Kezar Life Sciences Inc reports results for the quarter ended in December - Earnings Summary

Kezar Life Sciences

17/03/2022 21:01

* Kezar Life Sciences Inc  KZR.OQ  reported a quarterly
adjusted
loss of 25 cents​​ per share for the quarter ended in December.
The mean expectation of six analysts for the quarter was for a
loss of 30 cents per share.
    * Reported revenue was zero​;  analysts expected zero. 
    * Kezar Life Sciences Inc's reported EPS for the quarter was
a
loss of 25 cents​.
    * The mean earnings estimate of analysts had risen by
about 1.1%
in the last three months.​ 
    * In the last 30 days there have been no negative revisions
of
earnings estimates 
    * Kezar Life Sciences Inc shares had fallen by 12.0% this
quarter.
    * The company reported a quarterly loss of $14.21 million.
    * Wall Street's median 12-month price target for Kezar Life
Sciences Inc is $20.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated March 17 at 09:00 p.m.  ​All
figures in US dollars unless otherwise stated